Literature DB >> 11959562

Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.

G M Eliopoulos1, C B Wennersten.   

Abstract

Interactions between quinupristin-dalfopristin and six other antimicrobials were examined by checkerboard arrays against 50 clinical isolates of vancomycin-resistant Enterococcus faecium selected to represent a range of susceptibilities to individual agents. Unequivocal synergistic or antagonistic interactions at clinically relevant concentrations were infrequently encountered when the streptogramin was combined with chloramphenicol, ampicillin, imipenem, vancomycin, or teicoplanin. Combinations with doxycycline resulted in synergistic inhibition in 36% of checkerboards. Against 10 strains of Enterococcus faecalis, synergistic interactions were found when quinupristin-dalfopristin was combined with doxycycline (four strains), either glycopeptide (three strains), or ampicillin (two strains). Combination with quinupristin-dalfopristin increased the ampicillin MIC from 1 to 4 microg/ml for one strain. For 10 strains of E. faecium, interactions were also assessed by time-kill methods using concentrations of the agents attainable in human serum. Most of these antimicrobials augmented killing by quinupristin-dalfopristin to a minor degree. Against 2 of the 12 strains in this collection that were not highly resistant to gentamicin, the combination of quinupristin-dalfopristin (2 microg/ml) plus gentamicin (5 microg/ml) resulted in killing approaching 3 log(10) CFU/ml. With the exception of doxycycline, inhibitory interactions between quinupristin-dalfopristin and other agents tested against vancomycin-resistant strains of E. faecium were uncommon at clinically relevant concentrations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959562      PMCID: PMC127136          DOI: 10.1128/AAC.46.5.1319-1324.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.

Authors:  S O Matsumura; L Louie; M Louie; A E Simor
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci.

Authors:  C R Messick; S L Pendland
Journal:  Diagn Microbiol Infect Dis       Date:  1997-11       Impact factor: 2.803

3.  Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis.

Authors:  B Fantin; R Leclercq; L Garry; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium.

Authors:  V Lorian; F Fernandes
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

5.  In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.

Authors:  S L Kang; M J Rybak
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

6.  The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.

Authors:  R C Moellering; P K Linden; J Reinhardt; E A Blumberg; F Bompart; G H Talbot
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

7.  Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.

Authors:  F Caron; H S Gold; C B Wennersten; M G Farris; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

8.  Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure.

Authors:  J Millichap; T A Ristow; G A Noskin; L R Peterson
Journal:  Diagn Microbiol Infect Dis       Date:  1996-05       Impact factor: 2.803

9.  Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

Authors:  R N Jones; C H Ballow; D J Biedenbach; J A Deinhart; J J Schentag
Journal:  Diagn Microbiol Infect Dis       Date:  1998-07       Impact factor: 2.803

10.  Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.

Authors:  J R Aeschlimann; M J Zervos; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more
  3 in total

1.  RepTB: a gene ontology based drug repurposing approach for tuberculosis.

Authors:  Anurag Passi; Neeraj Kumar Rajput; David J Wild; Anshu Bhardwaj
Journal:  J Cheminform       Date:  2018-05-21       Impact factor: 5.514

2.  Boeravinone B, A Novel Dual Inhibitor of NorA Bacterial Efflux Pump of Staphylococcus aureus and Human P-Glycoprotein, Reduces the Biofilm Formation and Intracellular Invasion of Bacteria.

Authors:  Samsher Singh; Nitin P Kalia; Prashant Joshi; Ajay Kumar; Parduman R Sharma; Ashok Kumar; Sandip B Bharate; Inshad A Khan
Journal:  Front Microbiol       Date:  2017-10-04       Impact factor: 5.640

3.  Drug Resistance Reversal Potential of Nanoparticles/Nanocomposites via Antibiotic's Potentiation in Multi Drug Resistant P. aeruginosa.

Authors:  Pratima Pandey; Rajashree Sahoo; Khusbu Singh; Sanghamitra Pati; Jose Mathew; Avinash Chandra Pandey; Rajni Kant; Ihn Han; Eun-Ha Choi; Gaurav Raj Dwivedi; Dharmendra K Yadav
Journal:  Nanomaterials (Basel)       Date:  2021-12-30       Impact factor: 5.076

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.